Mast Therapeutics (MSTX) Reports Q4 Loss of $0.02/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Mast Therapeutics (MSTX) Reports Q4 Loss of $0.02/Share

Mast Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results

March 6, 2017 4:30 PM EST

SAN DIEGO, March 6, 2017 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2016.

"We are pleased with the progress made with AIR001 during the year and anticipate the closing of the merger with Savara to take place in the second quarter of this year," stated Brian M. Culley, Chief Executive Officer.  "We believe this merger offers our stockholders a diversified, late-stage product development pipeline with... More